The article discusses Prime Medicine, Inc. in relation to short selling and analyst sentiment. Prime Medicine, Inc. has seen positive developments with its gene editing drug, PM359, gaining FDA clearance.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing